68
Participants
Start Date
October 29, 2019
Primary Completion Date
May 31, 2022
Study Completion Date
June 30, 2022
Trifluridine Tipiracil
"Trifluridine-Tipiracil will be administered at 35 mg per square meter orally twice daily, with a glass of water within 1 hour after completion of morning and evening meals, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period. One treatment cycle with Trifluridine-Tipiracil consists of the following:~Days 1-5: Trifluridine / Tipiracil (35 mg/m2/dose) orally twice daily Days 6-7: Rest Days 8-12: Trifluridine / Tipiracil(35mg/m²/dose) orally twice daily Days 13-28: Rest"
Panitumumab 20 MG/1 ML Intravenous Solution [VECTIBIX]
Panitumumab will be administered as a 6 mg/kg intravenous infusion over 60 minutes every 2 weeks (q2w) of a 28-day cycle (Day 1 and Day 15).
AORN-Ospedale dei colli, UOC Oncologia, Napoli
A.O.U. Cagliari - Presidio Policlinico D. Casula, Monserrato
A.O.U. Pisana, Pisa
A.R.N.A.S. Garibaldi - P.O. GaribaldiNesima, Catania
Istituto Europeo di Oncologia, Milan
"A.O.U. dell'Università degli studi della Campania Luigi Vanvitelli", Napoli
"IRCCS Istituto Nazionale Tumori Fondazione G. Pascale", Napoli
Universiyà Campus-Biomedico, Roma
University of Campania Luigi Vanvitelli
OTHER